← Back to headlines
Arrowhead (ARWR) Stock Rated Buy on Metabolic Pipeline Potential
Arrowhead Pharmaceuticals (ARWR) has received a 'Buy' rating, based on the promising potential of its metabolic disease pipeline.
2 May, 17:51 — 2 May, 17:51
Sources
Showing 1 of 1 sources
